Onconetix, Inc.

Onconetix, Inc. is a commercial-stage biotechnology enterprise specializing in the research, development, and commercialization of solutions for men’s health and oncology. The company focuses primarily on Proclarix, an in vitro protein-based diagnostic blood test for prostate cancer that assesses risk to help determine the necessity of patient biopsies following inconclusive prostate-specific antigen results. While previously developing treatments such as a daily combination therapy for benign prostatic hyperplasia, the organization has discontinued those initiatives to concentrate on its core oncology diagnostic asset. Target end users include physicians, patients, and local diagnostic laboratories.

The firm conducts sales in Europe, where its diagnostic product is CE-marked and authorized under the In Vitro Diagnostic Regulation, and it anticipates marketing the test within the United States through an established laboratory licensing agreement. Corporate headquarters are situated in Cincinnati, Ohio, while manufacturing activities are outsourced to third-party commercial suppliers.

Summary of the business section of Onconetix's latest annual report, written by StockData.